Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The physical effects of diclazepam can be broken down into several components which progressively intensify proportional to dosage.
The cognitive effects of diclazepam can be broken down into several components which progressively intensify proportional to dosage. The general head space of diclazepam is described by many as one of intense sedation and decreased inhibition. It contains a large number of typical depressant cognitive effects. Paradoxical reactions to benzodiazepines such as increased seizures (in epileptics), aggression, increased anxiety, violent behavior, loss of impulse control, irritability and suicidal behavior sometimes occur (although they are rare in the general population, with an incidence rate below 1%). These paradoxical effects occur with greater frequency in recreational abusers, individuals with mental disorders, children, and patients on high-dosage regimes.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Diclazepam is described as extremely psychologically addictive. Compulsive redosing is commonly reported, and rebound anxiety following use can drive cycles of dependence and repeated administration.
Physical dependence develops with regular use and can become severe. Abrupt discontinuation after extended use is potentially life-threatening, with risks including hypertension, seizures, and death. Gradual tapering over weeks is essential for safely discontinuing use.
Diclazepam likely has low toxicity relative to dose when used alone. However, fatal overdose may occur when combined with other depressants such as alcohol, opioids, barbiturates, or other GABAergic substances. Benzodiazepine overdose is a medical emergency that may lead to coma, permanent brain injury, or death.
Paradoxical reactions including aggression, violent behavior, irritability, and loss of impulse control occur rarely, with an incidence rate below 1% in the general population. These effects are more common in recreational abusers, individuals with mental disorders, children, and those on high-dose regimens. Delusions of sobriety may occur at heavy doses.
Diclazepam possesses anticonvulsant properties during active use. Paradoxical increases in seizures may occur rarely in epileptics, with incidence below 1%. The primary seizure risk is during abrupt withdrawal from chronic use, where discontinuation without tapering can trigger potentially fatal seizures.
Diclazepam was first synthesized in 1960 by Leo Sternbach and his research team at Hoffman-La Roche, the same laboratory responsible for developing numerous other benzodiazepines including diazepam (Valium). Despite being created during the golden age of benzodiazepine discovery, diclazepam was…
Listed as a controlled benzodiazepine under Schedule IV of the Controlled Drugs and Substances Act. All benzodiazepines fall under this classification in Canada.
Classified under the IV-P group since January 27, 2022. Ownership, possession, and sale are illegal.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
Controlled as a Class C substance under the Misuse of Drugs Act since May 31, 2017. Possession, production, and supply are illegal.
Controlled under Anlage II of the Betäubungsmittelgesetz (Narcotics Act) since November 21, 2015. Manufacturing, possession, import, export, purchase, sale, procurement, or dispensing without a license is prohibited.
Controlled as a Schedule III substance since 2017 under Russian narcotics legislation.
Classified as a controlled drug substance. Possession, production, supply, and importation are prohibited.
Controlled as a Schedule I substance under the Controlled Substances Act since January 23, 2023. Classified as having high abuse potential with no currently accepted medical use.
13 sources cited
